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1. Introduction 
The continuous pathologic reduction of cerebral blood flow is mainly caused by 
thromboembolic occlusion of a brain-supplying artery or cerebral blood vessel disruption. 
These events, representing the most important causes for ischemic or hemorrhagic strokes 
respectively, lead to an acute breakdown of neuronal function, secondary brain damage by 
numerous mechanisms and the loss of cerebral tissue. In industrialized nations, stroke 
accounts for every third case of death. Cerebral stroke furthermore represents the most 
frequent reason for permanent disability in adulthood (Kolominsky-Rabas et al., 2006) and 
is therefore considered to be one of the most dreaded diseases from a clinical, socio-
economic and individual, patient-related perspective.  
1.1 Current state of the art clinical stroke treatment and diagnosis 
Intravenous thrombolysis by tissue plasminogen activator (tPA) is currently the only FDA-
approved, effective and potentially curative treatment (Blinzler et al., 2011) for ischemic 
stroke. However, this approach is restricted to a narrow time window of 4.5 hours (Hacke et 
al., 2008). The approach is further limited by a sharply increasing number needed to treat 
(Hacke et al., 2008; Lansberg et al., 2009) and a significant risk for fatal adverse events 
(Shobha et al., 2011) at later stages of this time window. As a result, more than 95% of all 
stroke patients do not significantly benefit from systemic thrombolytic treatment (Barber et 
al., 2001). Alternatively, endovascular thrombolysis under thorough radiological 
surveillance can be applied in specialized centers, extending the therapeutic time window to 
up to 8.0 hours under optimal conditions (Natarajan et al., 2009).  
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Cerebral ischemia needs to be discriminated from hemorrhagic stroke by means of magnetic 
resonance imaging (MRI) or computer tomography (CT) prior to the start of therapy, as 
inducing thrombolysis after hemorrhagic strokes is fatal. The mentioned imaging modalities 
are also used to monitor disease progression and the beneficial, or eventually detrimental, 
impact of any therapeutic intervention.  
Even though intracerebral hemorrhages are treated by multimodal strategies including 
neurosurgical interventions and diligent monitoring of blood pressure (Flower & Smith, 
2011), the event is still associated with high morbidity and mortality rates (Rymer, 2011), 
leaving about 80% of patients dead or disabled. Repeated patient surveys by MRI or CT is 
therefore pivotal for early detection of complications after hemorrhagic stroke. In summary, 
imaging procedures are of utmost clinical importance for diagnosis, treatment and onward 
care after ischemic and hemorrhagic strokes.  
1.2 Current recommendations for preclinical stroke research 
Preclinical and translational stroke research aims to overcome the aforementioned 
therapeutic and prognostic limitations by the development of novel treatment strategies. 
The application of stem cell based therapies is currently among the most promising 
approaches in the field (Burns & Steinberg, 2011) and the first clinical trials have already 
been initiated (Sahota & Savitz, 2011). However, despite thorough research, the 
development of novel stroke therapies is so far characterized by continuous setbacks and the 
general failure to translate promising findings from animal models into effective clinical 
treatment paradigms (Del Zoppo, 1995). In particular this holds true for the development of 
neuroprotective therapies (O’Collins et al., 2006).  
The inability to translate preclinical findings into clinical therapies has been a matter of 
debate for more than 15 years. International expert committees like the “Stroke Treatment 
Academic and Industry Roundtable” (STAIR) and “Stem Cell Therapies as an Emerging 
Paradigm in Stroke” (STEPS) consortia were formed to define, discuss and publish 
recommendations for adequate preclinical stroke research (The STAIR Participants, 1999; 
The STEPS Participants, 2009). Current guidelines for state of the art assessment of novel 
stroke treatment strategies comprise the design and application of relevant animal models 
(Fisher et al., 2009), the definition of the optimal route of administration for any therapeutic 
agent (Savitz et al., 2011; The STAIR Participants, 1999), as well as the choice of relevant 
imaging protocols to monitor therapeutic safety and efficacy (Savitz et al., 2011).  
1.3 The role of large animal models in translational stroke research 
Cerebral ischemia is mainly modeled by transient or permanent occlusion of the middle 
cerebral artery (MCA; Howells et al., 2010). Rodent models are widely available and 
represent experimental key systems for preclinical stroke research. These models offer many 
advantages such as well established methodology including surgical techniques, imaging 
procedures, histological techniques and protocols for molecular biology. Further, the 
availability of genetically modified strains and excellent tools to assess functional outcome 
favor the use of rodent stroke models.  
However, the impact of a particular therapy in the gyrencephalic brain can only be assessed 
in large animals. Therefore, the use of a second, predominantly large animal species has 
been recommended by the STAIR and STEPS committees. Existing large animal models 
include rabbit (Amiridze et al., 2009), canine (Kang et al., 2007), feline (Garcia et al., 1977), 
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and porcine (Imai et al., 2006) models for which middle cerebral artery occlusion (MCAO) 
techniques have been described. For anatomical reasons, most large animal models require 
enucleation and show high mortality rates (The STAIR Participants, 1999), rendering their 
applicability for long term safety and efficacy trials difficult.  
Early models of cerebral hemorrhage were reported more than 45 years ago (Klintworth, 
1965), using the application of mechanical force (e.g. balloon inflation) to induce cerebral 
hemorrhages. More contemporary models are often based on atlas-guided stereotaxic 
injections (Bullock et al., 1984) of autologous blood or bacterial collagenase into cerebral 
tissue, predominantly the rodent striatum (MacLellan et al., 2010). MR-guided application 
techniques have recently been reported in primates (Zhu et al., 2011) but are rarely used, 
presumable due to ethical and financial restrictions. 
1.4 The ovine stroke model and its use for preclinical research  
To compensate the above mentioned common limitations of large animal models an ovine 
model of ischemic stroke using permanent MCAO was developed by our group (Boltze et 
al. 2008). This model avoids enucleation and allows for long term observation of subjects 
due to minimal mortality rates.  
Briefly, the method can be described as follows. A transcranial access is performed between 
the left eye and ear. Animals should be placed on the right side to avoid ventilation 
insufficiency due to a gaseous rumen edema during surgery. After superficial shaving and 
disinfection, the temporal muscle is incised at the Linea temporalis and temporally elevated 
from the parietal skull bone. Then, a trepanation of about 1 x 1 cm is performed right behind 
the orbital rim. After careful incision of the dura mater, the MCA is permanently 
electrocoagulated by a bipolar forceps. Occlusion of either one or two MCA branches or the 
entire cortical vessel allows a detailed control of lesion size and functional deficits (Boltze et 
al., 2008). The drill hole may be sealed by sterile bone cement after suturing of the dura. 
However, leaving the craniotomy open (only covered by the temporal muscle) avoids 
pathophysiological increase of intracerebral pressure in early post-stroke phases, 
significantly reducing post-stroke mortality. After refixation of the temporal muscle at the 
Linea temporalis and suturing the skin wound, the animals can be taken back to the stable 
and are allowed to recover. Adequate post stroke analgetic and antibiotic treatment has to 
be ensured. For any details regarding animal medication, behavioral phenotyping, 
advanced imaging and the surgical procedure itself, please refer to Boltze et al. (2008).  
Species-appropriate housing can be realized with comparatively low efforts and over 
extended time periods. The price per sheep is relatively low and the species is broadly 
available. A special feature of the sheep stroke model is the control of lesion size and 
subsequent behavioral deficits by occlusion of the cortical MCA or a defined number of its 
branches. A protocol for testing and quantification of neurological functions is available to 
assess the impact of the MCAO modality and a potential therapeutic procedure. Moreover, 
the model is eligible for detailed MR, CT and positron emission tomography (PET) studies 
as well as the assessment of autologous cell therapies.  
2. Stereotaxy and cell tracking for stroke-related applications 
Stereotaxic concepts were developed as minimally invasive surgical approaches which use 
three-dimensional Cartesian or polar coordinate systems to localize small targets inside the 
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body. The approach can be used for both diagnostic and therapeutic applications, as it 
allows the placement or the removal of a specimen from a certain location within the body 
with highest precision and minimal damage to the surrounding tissue. Stereotaxy is of 
particular importance in neurosurgery where the technique is routinely used for diagnosis 
and treatment of intracranial tumors (Willems et al., 2006), as well as for the application of 
deep brain stimulation electrodes in Parkinson’s disease (Starr et al., 1998) and neuropathic 
pain (Stadler et al., 2011). The fibrinolytic evacuation of intracranial hemorrhages by a 
stereotaxic apporach has also been reported (Samadani & Rohde, 2009). Moreover, 
stereotaxic stem cell injections into the human brain are used in phase I and II clinical trials, 
as the local administration of therapeutic compounds close to the lesion is considered to be 
advantageous. 
Albeit these concepts may have been strongly perpetuated towards clinical application 
clinical trials during the last years; the first reported results unfortunately resemble the 
translational failures that were known from past efforts. This holds true for experimental 
treatments in the field of stroke (Kondziolka et al., 2005) and Parkinson’s disease (Gross et 
al., 2011) although these concepts were positively evaluated in preceding rodent studies. 
This emphasizes the relevance of large animal models as an important translational 
milestone. Whereas simplified stereotaxic devices based on brain atlases are widely 
available for rodents, the accuracy and complexity of human stereotaxic devices can 
currently only be modeled in primates. However, this complexity, including the individual, 
“lesion-specific” application of substances or the induction of phenotypically varying 
intacerebral hematomas may be critically needed in translational research to mimic the more 
heterogenic patient populations enrolled in clinical trials.  
We expanded the sheep model to fill this methodological gap and to provide an additional 
large animal model for translational research in cell transplantation after ischemic stroke 
and intracerebral hemorrhages. Our model allows precise, MR-guided implantation of 
magnetically labeled, bone-marrow derived mesenchymal stem cells (stroke treatment) and 
autologous blood samples into the ovine brain (hemorrhage induction). The technique was 
developed using the BrainsightTM neuronavigation system (Rogue Research Inc., Quebec, 
Canada) and several modifications were applied to adapt the system to the ovine skull 
anatomy. Cell tracking can be performed reliably using clinical MR scanners with adequate 
resolution and sensitivity. 
This chapter describes the methodology of image-guided frameless stereotaxic surgery in 
sheep with special emphasis on (i) the application of an autologous therapeutic cell 
population (e.g., the mesenchymal stem cells), (ii) the previous labeling and subsequent 
imaging protocols for MR-based cell tracking in sheep and (iii) the MR-guided induction of 
cerebral hemorrhage in the species. 
3. Technical description of surgery 
3.1 General information about the species and handling requirements 
The neurosurgical approach for stereotaxy in sheep requires hornless subjects for easy 
accessibility of cranial structures. Merino sheep may be of advantage as many hornless 
strains can be found in this widely available race. Adult merino sheep weigh approximately 
80 kilograms (ewe) to 130 kilograms (rams) and have a wither height of about 0.9 meter. 
This body size allows for relatively easy handling. Frequent and early contact to humans 
facilitates familiarization and improves the handling. Species appropriate housing, feeding 
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as well as thorough medical inspections and blood screening, medication and vaccination 
ensure a significant reduction of postoperative complications and thereby enhance study 
quality (Boltze et al., 2008).  
Anesthesia is performed as described elsewhere (Boltze et al., 2008). Animals should be 
intubated after induction of anesthesia and placed in a prone (“sphinx”) position during 
surgery and imaging. Vital parameters (electrocardiogram, oxygen saturation, blood 
pressure, rectal body temperature) should be continuously monitored during any surgical 
intervention.  
3.2 Frameless stereotaxy in sheep – preparation and data acquisition 
The neuronavigation device, BrainSightTM, is a frameless system that allows for MRI data set 
based planning of surgical approaches as well as for surveillance and precision control of 
the surgical intervention with an optical position sensor (Frey et al., 2004). An individual 
3D-reconstruction of the head, especially the brain, is required for the precise planning and 
performance of the sterotaxic injections.  
3.2.1 Fiducial marker positioning and imaging 
The MR-compatible fiducial markers are attached to a maxillary splint (Fig. 1a). The use of 
the splint is different from neurosurgical approaches in human medicine, where fiducial 
markers can be fixed directly to cranial bones. This is not recommended in animals due to 
safety and welfare issues, especially when the animal is awake between MRI data set 
acquisition and surgery. The maxillary splint consists of a mouthpiece (Fig. 1a, 1) and two 
angled arms (Fig. 1a/b, 2) that hold the fiducial markers (Fig. 1a/b, 4). The mouthpiece is 
inserted carefully, avoiding damage to or constriction of the tracheal tube. It can be adapted 
to the individual shapes of the maxillary molars and the hard palate by using thermoplastic, 
which cures within a few minutes. The fiducial markers are usually placed in the area 
between the cheeks and the ears. The maxillary splint has to be adapted to each individual 
sheep to ensure maximum precision. The splint has to be inserted for imaging and surgery.  
 
 
Fig. 1. Maxillary splint with fiducial marker 
a) maxillary splint with mouthpiece (1), angeled arms (2), bar spacer to the skin (3) and 
fiducial marker (4); b) sheep before surgery, the maxillary splint is inserted and fixed with a 
bandage. The angeled arms (2) support the fiducial markers (4); c) 3D-MRI reconstruction of 
the skin illustrates the position of fiducial makers between cheek and ear (black arrow 
heads) 
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It should be fixed with bandages to ensure an accurate, stable and reproducible position. 
Otherwise, even minor displacements of the fiducial markers may lead to large divergences 
between planned and realized target. 
A 1.5 T scanner is sufficient for MRI data set acquisition even though the use of a 3 T 
scanner is recommended. The optimal time span between data acquisition and surgery 
should be long enough for animal recovery from imaging anesthesia. However, for cell 
transplantation after MCAO, this time span must not be too long to stay within a potential 
therapeutic time window. Usually, a recovery phase of one day is sufficient, but longer 
recovery phases should be scheduled if permitted by the experimental design.  
After initial anesthesia and transport, the sheep is placed on the scanner table and is fixed 
using adhesive tape (cloth tape tesa®, Tesa SE, Hamburg, Germany) on shoulder and hip, 
which can be easily removed from the wool. The sheep is covered by a drape which offers 
limited protection from cooling and prevents soiling of the scanner. For subsequent target 
planning, a high-resolution T1-weighted 3D sequence is acquired with a minimum 
resolution of 1 x 1 x 1 mm. Acquisition time depends on the number of averages, but usually 
does not exceed 30 minutes. Additionally, an acquisition of an angiographic sequence is 
recommended in order to avoid damaging major intracerebral vessels during surgery (see 
paragraph 3.2.2). 
3.2.2 Planning of surgery 
The BrainSightTM software (V2.1) consists of a graphical user interface with a tab based 
arrangement of modules (Fig. 2a, red rectangle). Pre-surgical image processing includes 
several steps that are explained in detail in the following paragraph. 
After starting the software, the MRI data set has to be loaded. Therefore, click of the 
“Anatomical” tab (Fig. 2a, 1): 
1. Select MRI 3D data set by pressing “Choose” and load the data. 
2. Identify positioning of animal by clicking on “Show Image & Detail” (Fig. 2a, 2). 
3. Choose the radio button which corresponds to the correct animal position (e.g. “actual” 
orientation  Sphinx Heads First; “scanner” orientation  supine head first) 
To avoid accidental intrasurgical damage of major cerebral arteries, an overlay with an 
angiographic data set is recommended. Therefore, use the “Overlays” tab:  
1. Implement the data set by clicking “Load Overlay”. 
2. Define the desired opacity by choosing the corresponding slider. 
In the next step, anatomical structures can be defined by segmentation. While the skin 
reconstruction is performed automatically, other relevant anatomical structures like the 
brain and cranial bones have to be identified separately and on each slice. Select the “ROIs” 
(=region of interest) tab to perform this operation: 
1. Press “New ROI from Region Paint”. 
2. Name the ROI (e.g. “brain”). 
3. Choose a threshold of grey value to localize the structure by moving the slider (Fig. 2b, 
3). 
4. The opacity of the selection can be changed by the corresponding slider (Fig. 2b, 4). 
5. Start segmentation of the threshold areas in the middle of the brain by pressing on the 
“Seed Tool” icon (Fig. 2b, 5) and select the threshold area of the brain. 
6. If necessary, correct the segmentation manually using the “Erase pencil”. Cut the 
unwanted conjunction between target and non-target structures and clear all non-target 
structures using the “Erase Fill” tool (Fig. 2b, 5). 
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7. Choose the next slice. 
8. Repeat points 5 to 7 for each MRI slice until all areas of the specific structure are 
completely selected. 
9. Repeat steps 1 to 8 for any other target (e.g. bone, see below). 
 
 
Fig. 2. BrainSightTM software applications I 
a) Graphical user interface with tab based modules (red rectangle), “Anatomical” tab (1), 
“Show Image & Detail” button (2); b) “ROIs”: reconstruction of the brain from MRI data set, 
slider of grey value threshold (3), slider of opacity (4), icon tools (5) 
3D reconstructions are created after defining the ROIs. A skin reconstruction is necessary to 
register the fiducial markers. It is recommended to render 3D reconstructions from brain 
and bone. Use the “Reconstruction” tab as follows: 
1. Skin reconstruction is performed automatically by choosing “Surface Skin”. Use the 
threshold slider to suppress inclusion of air and/or wool in the skin rendering. Press 
“Compute skin” and subsequently name the reconstruction (e.g. “skin”). 
2. Bone and brain are calculated by selecting “Surface from ROIs”. Label the generated 
surface as “bone” and “brain”. Choose corresponding ROI from the “Select button” and 
press “Compute Surface”. 
The MRI-positive fiducial markers need to be relocalized manually in the MRI data set. 
The tagging of these pivotal landmarks requires maximum precision. Use the 
“Landmarks” tab: 
1. Switch the layout to “1|3 windows”. 
2. Skin surface reconstruction should be opened in the large left window by choosing 
“Skin” of the select button (Fig. 3a, 1).  
3. MRI data sets are now opened in three windows on the right side. Select “Inline & All 
Landmarks” in the upper, “Inline 90 & All Landmarks” in the middle and 
“Perpendicular & All landmarks” in the bottom window. You may wish to zoom out 
the fiducial marker for better view of their position. 
4. Choose “sphere” from the select button (Fig. 3a, 2) as the shape of the fiducial markers. 
Coordinate system is “Brainsight” (preselected). 
5. Press “New” (Fig. 3a, 3). The compiled landmarks will be named automatically.  
6. Select a landmark position by choosing a fiducial marker in the skin reconstruction. It 
will be marked with a sphere. The crosshair in the MRI data now indicates the 
corresponding position in all views. Correct the relative position of the fiducial marker 
in each view using the sliders on the right hand side of the screen (Fig. 3a, 4). Position 
the cursor so that the crosshairs perfectly represents the middle of the fiducial marker in 
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the upper “Inline & All Landmark” frame and the “Inline 90 & All Landmarks” using 
the using the “AP” (anterior/posterior) and the “Lat” (medial/lateral) slider.  
7. Press “New” for a new landmark and repeat step 6 until all fiducial markers are 
identified as landmarks by the software. 
 
 
Fig. 3. BrainSightTM software applications II 
a) identification of landmarks by MR images using the “landmarks” tab, select button of 
window view (1), select button of the shape of the fiducial marker (2), “New” button (3), 
sliders for positioning (4); b) definition of targets and trajectories in MRI and 3D 
reconstructions of skin, bone and brain, sliders for positioning (5), select button of marker or 
trajectory (6) 
The last step of the planning procedure is the identification of the surgical targets according 
to the study design. In addition, optimal trajectories are planned during this step. The 
following recommendations for accessing the target should be considered to ensure a 
minimal invasive surgical procedure and to avoid surgical problems and complications:  
i. Avoid the perforation of the horn plate, even hornless animals have one. 
ii. Avoid the perforation of the frontal sinus. 
iii. Avoid a trajectory that crosses major vessels (as identified by the angiographic overlay).  
iv. Avoid cerebral sulci. 
The route to the target (trajectory) and the target itself (marker) should be defined as follows 
using the “Targets” tab: 
1. Switch to a 2 x 3 layout and arrange the frames as follows: MRI data are shown in the 
upper row and the reconstructed objects in the bottom row. Select “Coronal & All 
Targets” in the 1st, “Inline 90 & All Targets” in the 2nd and “Inline & All Targets” in the 
3rd upper frame. Select “Skin & All Targets”, “Bone & All Targets” and “Brain & All 
Targets” in the bottom row. 
2. Coordinate system is “Brainsight” (preselected). 
3. Place the crosshair at your target (since a homogeneous MRI signal from the target 
structure is preferred for the cell tracking experiments, the Corona radiata was used in 
this example).  
4. Use the sliders (Fig. 3b, 5) to place the trajectory (arrow in the crosshair) and make sure 
it is chosen with respect to the aforementioned recommendations. Ascertain the 
position of the trajectory in each frame and correct the access using the “AP”, “Lat” 
(lateral) and “Twist” sliders.  
5. Choose ”Trajectory” in the select button (Fig. 3b, 6) to confirm the planned trajectory. 
The trajectory is named automatically. 
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6. Choose ”Marker” from the select button (“New” is preselect) to define the target point. 
The marker is named automatically. 
7. Repeat steps 3 to 6 for more trajectories and markers. 
Finally, the project should be saved to a specified folder (Menue  “File”). 
3.3 Frameless stereotaxy in sheep – surgical procedure 
3.3.1 General surgery  
The BrainsightTM hardware comprises an optical position sensor and a number of surgical 
devices (Fig. 4). During surgery the anesthetized sheep is placed in the prone position on the  
 
 
Fig. 4. BrainsightTM hardware 
a) The peripheral hardware of BrainsightTM system comprises a computer and an optical 
position sensor (Polaris®); b) Additionally, a drill guide (not shown) and a ruler guide are 
available on request; c) The surgical instruments and hardware  
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operating table. On smaller tables, fix the animal with adhesive tape in the shoulder and hip 
region. The head rests on a foam rubber pad to ensure a stable and correct position. The 
upper head of the animal needs to be shaved and disinfected. Next, the maxillary splint has 
to be placed precisely in the mouth (ensure its correct position) and it should be fastened 
tightly with a bandage.  
A rigid half-circular clamp (c-clamp) is used for fixation of the head and to provide support 
for the articulated arm. A similar holder system with skull pins is also used for 
neurosurgical procedures in humans (Olivier & Bertrand, 1983). The c-clamp is fixed to the 
skull bone by at least four adjustable skull screws. To avoid skull damage the screws are 
positioned at distinctive spots (e.g. beneath the Linea temporalis and ventral of the 
Protuberantia occipitalis externa, Fig. 6a). After fixing the c-clamp to the skull, the whole 
assembly is attached to the operating table using the adjustable mounting system. The 
system allows to lock the c-clamp, and thereby the skull in the appropriate position. Next 
the articulated arm is mounted at the c-clamp. Ensure that the entire field of surgery can be 
reached by the arm. Thereafter, the tracker (containing three track balls which can be 
recognized by the optical position sensor) is positioned at the c-clamp to act as a fixed 
optical reference for the coordination system. The system is now ready for merging the 
virtual MRI data with the spatial position of the sheep’s head. The previously processed 
data sets (MR images, predefined landmarks and targets) have to be reopened by using the 
“File” option (“Open Project”) in the menu. Choose the “Session” tab: 
1. Choose “New Online Session” from the select button. 
2. Select all “Targets in project” in the opened frame and move them to “Targets to sample 
in this session” via the drag and drop operations. 
3. Press “Next Step” to enter the “Polaris” submodule in the “Session”. A new frame will 
be opened automatically. 
Next, the Polaris® optical position sensor has to be configured and adjusted: 
1. Make sure the “Polaris status” is “ok” (Fig. 5a, 1) and that all tools (pointer, subject 
tracker) are located in the detection space (visible field). Otherwise press “Reset 
Polaris”. 
2. The tracker (fixed to the c-clamp) should be placed in the middle of the visible field by 
moving the Polaris camera. Ensure the correct position of the subject tracker in 3D, top, 
lateral and frontal view. Make sure that the visible field is wide enough to track the 
pointer when navigating in the periphery of the head. To check this move the Pointer in 
the 3D field of view). 
3. Press “Next Step” (Fig. 5a, 2) to enter the “Registration” module. 
Next steps require the spatial allocation of the surgical object (head) and MR images. 
Therefore, the registration of (physical) fiducial markers with the already defined virtual 
landmarks is performed as follows: 
1. Switch the layout to 1|3 windows and use the same window allocation as during 
landmark tagging. 
2. Perform manual registration update.  
3. Select one landmark from the list. The correct selection will be confirmed acoustically. 
The specific landmark is now displayed and marked in each window. 
4. Place the tip of the pointer in the divot of the corresponding fiducial marker. This is the 
most important step to ensure precision of the surgical approach. The pointer has to be 
placed orthogonally to the divot in each dimension. Avoid any pressure on the fiducial 
marker, which may alter its position. Make sure the pointer can be detected by the 
www.intechopen.com
Frameless Stereotaxy in Sheep –  
Neurosurgical and Imaging Techniques for Translational Stroke Research 
 
31 
optical position sensor. Make sure that the pointer does not move when recording the 
location of a fiducial markers. 
5. Press “Sample & Go to next landmark”. 
6. Repeat Point 3 to 5 until all landmarks are co-registered with the fiducial markers. 
7. Press “Next Step” to enter “Validation” procedure of the registration (see below). 
The allocation of the landmarks and fiducial makers is validated as follows: 
1. Arrange a 2 x 3 layout. 
2. Place the pointer randomly in the divot of each fiducial marker. After ideal co-
registration, the pointer tip should now precisely indicate the corresponding landmark. 
Check the distance of the pointer tip to the corresponding landmark. A vector drift of 
1.6 mm can be tolerated, but a difference of <1.0 mm is strongly recommended while a 
deviation of <0.6 mm is optimal. Repeat the “Registration” in the case of >1.6 mm 
vector deviation or to ensure demanded precision.  
3. To check for lateral deviation in registration of the subject’s head, place the pointer on 
the skin surface at a virtual line between the eyes. Three points per side are 
recommended. Control the distance in the “Coronal” view, in the “Inline” view and in 
the “Skin” reconstruction. Repeat the registration in case a unilateral shift is noticed. 
4. For longitudial deviation, place the pointer at several points on the skin (six are 
recommended) in the midline of the cranium. Control the distance in the “Sagital” 
view, in the “Inline” view and in the “Skin” reconstruction. Repeat the registration in 
case of a dorsoventral shift. NOTE: Skin thickness may be altered due to the animal 
being fixed in the c-clamp, causing the occipital skin to be pulled tautly or to bulge. This 
may alter the preceived skin thickness.  




Fig. 5. BrainSightTM software applications III 
a) Screenshots taken during the setting of the Polaris® optical position sensor. The tracker 
and the moveable pointer have to be located in the 3D field. Polaris status (1), “Next Step” 
button (2); b) For adjustment of trajectory and target (3) within the “Session” tab, the red 
“Bullseye” (4) has to overlap with the green crosshair as shown 
Following this step, adjust the surgical access and the targets. Recall the planned targets in 
the software interface: 
1. Arrange a 2 x 3 layout as follows: upper row comprises “Coronal & samples”, “Inline 90 
& samples” and “Inline & samples”. Bottom row contains “Bullseye”, “Skin & samples” 
and “Bone & samples”.  
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2. Check that the coordinate system is “Brainsight”, driver is “Pointer”, and Crosshair is 
“Needle”. 
3. Select the first trajectory (Fig. 5b, 3). 
4. Place the pointer in the articulated arm for adjustment of the trajectory (Fig. 6b). The 
pointer represents the needle to be inserted during surgery. Make sure the pointer is 
both locked in the chuck and located in the visible field. 
5. Place the pointer tip next to the expected surgical access (drill hole) position by moving 
the articulated arm. After approximate adjustment, ascertain that the “Bullseye” (red 
circle) overlaps with the green crosshair. 
6. Use the x-y stage to optimize the position. Make sure the red dot of the “Bullseye” 
aligns with the crosshair (Fig. 5b, 4).  
7. Lock the articulated arm and place the stabilizing pin in the guide. Ensure that all 
hardware pieces are in the correct position and tightly locked now. 
8. Measure the thickness of the cranial bone at the level of access in the “Inline 90 & 
samples” view on the computer. In order to avoid damage to the dura mater or the 
brain by drilling to deep you may wish to underestimate bone thickness by 0.5 mm. 
 
 
Fig. 6. Surgical set-up in sheep 
a) Position of the c-clamp, fixed with 4 skull screws beneath the Linea temporalis and 
Protuberantia occipitalis externa, note the tracker on the right side of the c-clamp; b) The 
articulated arm is mounted on the c-clamp and additionally fixed by a sharp stabilizing pin 
(black arrow). The pointer (white arrow) is placed in the articulated arm at the desired 
trajectory. c) Drill guide (white arrow) for manual drilling is placed in the arm  
(Please note that the subject’s head is not covered by surgical drape for better illustration) 
The skin above the desired access is locally incised. The incision usually does not exceed one 
centimeter. The periosteum is removed using a Willigers raspartory. You may use small 
retractors for better accessibility. For skull trepanation, adjust the drill guide to the 
measured bone thickness, mount it at the end of the articulated arm and place it directly on 
the exposed skull surface. Drilling is performed at lower speed (10,000 rpm or less, for 
example using a Microspeed® uni, Aesculap AG, Tuttlingen, Germany). Since minor 
deviation between measured and real bone thickness can occur, the dura mater may not be 
reached after drilling. In that case, carefully continue with manual drilling (Fig. 6c). The 
correct position of the drill hole within the planned trajectory should be checked by placing 
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the pointer tip in the drill hole. In case of minor deviation, the drill hole can be easily 
expanded during this step. 
Next, the distance from the drill hole to the intracerebral target must be measured. Place the 
pointer tip in the drill hole at the level of the skull surface, not the level of the dura. The 
distance between the pointer tip and the target should now be displayed on the computer. 
Thereafter, a ruler guide with digital display is placed in the articulated arm. The 
instrument to be inserted into the brain, for example a filled Hamilton syringe (see 3.3.2), is 
mounted at the ruler guide. The tip of the instrument (e.g. a syringe cannula, Hamilton 
Company USA, Reno, USA) has to be positioned at the level of the skull surface, as done 
with the pointer tip for distance measuring. Now, set the digital display to zero for 
reference. The cannula can be inserted to the desired depth (Fig. 7).  
 
 
Fig. 7. Application equipment with ruler guide and Hamilton syringe. The syringe is 
inserted to a depth of 29.2 mm in the given example. 
This should be done in a slow and steady manner to avoid microbleedings and injuries. Do 
not advance faster than 2 mm per minute. In case you want to inject any kind of substance 
or cell solution (as in the example given in 3.3.2) this should also be done slowly, ideally 
using a micropump at a maximum pump rate of 5 µl per minute. The cannula is left in 
position for another ten minutes to allow the injected substance to diffuse locally. The 
explantation of the cannula is done according to the implantation. Repeat all steps above for 
multiple insertions. Verify the trajectory for each individual injection. At the end of the 
surgery, the drill hole is plugged with sterile bone wax, the articulated arm and the c-clamp 
are removed carefully by detaching the screws, and the skin wounds are sutured. Before the 
animal awakes from the anesthesia, the maxillary splint is carefully removed and the sheep 
receives postoperative medication with antibiotics and analgesics for 5 days. 
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3.3.2 Exemplary applications  
Exemplary application for stereotactically guided (cell or blood) depostions following stroke 
and other cerebral disorders are an emerging field of research in regenerative medicine. This 
route of administration is expected to be used in upcoming clinical trials. The sheep model 
allows the simulation of autologous cell therapies, in particular using intracerebral 
stereotactic cell delivery. This may be required for example when cell depots need to be 
placed next to a lesion site, which may vary between individual cases.  
In the described stereotactic model, autologous bone marrow stromal cells (BMSC) were 
chosen as an example since these cells were reported to be benefical after stroke treatment 
and neurodegenerative diseases (Joyce et al., 2010). Also other cell types like neural or 
embryonic stem cells were used for local transplantation close to the infracted area border 
(Guzman et al., 2007) or into the contralateral hemisphere (Hoehn et al., 2002) in rodent 
models. After purification and cultivation (see 4.1.1), a defined cell number is suspended 
and stored in a Hamilton syringe with a 15.6 cm long cannula. The technique of stereotactic 
transplantation is described in 3.3.1. For post-translational tracking, the cells can be labeled 
with iron oxide nanoparticles such as VSOP (very small superparamagnetic ironoxide 
particles, Ferropharm, Germany) (see 4.1.1). The localization and migration of transplanted 
cells is monitored by MRI (see 4.1.2).  
Alternatively, the stereotactic device can be used to model cerebral hemorrhage by application 
of blood into the sheep brain. For that purpose, autologous blood is collected from an arterial 
(preferred) or venous line in a heparinized syringe and is transferred to a Hamilton syringe 
before application. The steps are technically identical with the injection of cells (see 3.3.1). The 
injected blood volume depends on the planed region and the target dimensions, but should 
not exceed two milliliters in sheep (approx. weight of sheep brain: 120 g).  
4. Application examples 
4.1 Concept 1: Cell labeling for MRI-based tracking in vivo 
4.1.1 Harvesting and processing of Bone Marrow Stromal Cells (BMSC) 
Autologous cell harvest and cell processing 
BMSC are commonly isolated from bone marrow aspirates. Bone marrow samples may be 
harvested from the iliac crest in humans and in sheep. Therefore, the puncture area on both 
iliac crests are shaved and disinfected while the anesthetized sheep is placed in a prone 
position. Samples of approximately 10 mL of bone marrow are taken from both sides by 
multiple punctures using a heparinized syringe. Higher aspiration volumes from single 
punctures may result in contamination with peripheral blood. In the next step, the 
mononuclear cells (MNC) are isolated by density gradient centrifugation, which should be 
done within one hour after bone marrow harvest. A protocol for the separation of ovine 
MNC is stated below. 
1. Dilute bone marrow with phosphate buffer saline (PBS, Biochrom KG seromed®, Berlin, 
Germany) at a 1:1 (v/v) ratio. 
2. Merge Biocoll (1.077 g/mL, Biochrom KG seromed®, Berlin, Germany) and Pancoll 
(1.091 g/mL, PAN-Biotech GmbH, Aidenbach, Germany) in a ratio of 1:1 (v/v) to 
obtain a density of 1.084 g/mL (separation medium). Add 7 mL of mixed separation 
medium into a 50 mL falcon tube. 
3. Carefully place a layer of 10 mL of diluted bone marrow onto the gradient mixture. 
Avoid commixture between cell layer and the separation medium. 
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4. Centrifuge at 1,000 x g for 25 min. 
5. Carefully transfer the interface layer of mononuclear cells to a sterile centrifuge tube by 
using a sterile pipette (Fig. 8a). 
6. Wash cells twice in PBS. 
7. Count MNC. 
The BMSC population is isolated from MNC based on its ability to adhere to the cell culture 
flask. For that reason, MNC are seeded at a density of 5 x 10E4/cm2 in a culture flask. Cells 
are cultivated with DMEM (high glucose, PAA Laboratories GmbH, Pasching, Austria), 10% 
FCS (Invitrogen GmbH, Darmstadt, Germany) and 1% penicillin/streptomycin (PAA 
Laboratories GmbH, Pasching, Austria) at 37°C and 5% CO2 for 14 days. Two days after 
seeding, all non-adherent cells are removed by two washing steps with PBS.  
 
 
Fig. 8. Density gradient centrifugation of bone marrow and Prussian Blue staining of BMSC 
a) Density gradient centrifugation of diluted bone marrow: segmentation before and after 
centrifugation (supernatant: serum and platelets, sediment: erythrocytes and granulocytes) 
is displayed; b) cultivated, unlabeled, ovine BMSC stained with Prussian Blue (PB) and 
eosin; c) VSOP-labeled BMSC stained with PB and eosin; scale bar: 50 µm 
Cell labeling 
Very small superparamagnetic iron oxide particles (VSOP, Ferropharm, Teltow, Germany) 
are used for magnetic cell labeling. VSOP consist of a 5 nm iron oxide core coated by 
monomer citrate (total diameter of 9 nm) with a negative surface charge. Iron particle 
incorporation by the cells causes a strong decrease in the transverse relaxation time, which 
results in signal loss in T2*-weighted MR imaging (Arbab et al., 2003; Bowen et al., 2002; 
Renshaw et al., 1986). No apparent long-term cytotoxic effects were observed after using the 
particles both in vitro and in vivo (Fleige et al., 2002; Stroh et al., 2004 and 2009). For 
magnetic labeling sterile VSOP are added to the incubation medium. Addition of lipofection 
agents is not required for BMSC labeling. Cells are incubated with VSOP at 37°C and 5% 
CO2 for 90 minutes. After incubation, the cells are washed three times with PBS to remove 
any remaining VSOP not endocytosed by cells. The cells are harvested by incubation with 
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trypsin (Invitrogen GmbH, Darmstadt, Germany) for 5 minutes and centrifugated at 350 x g. 
To visualize the incorporated iron oxide particles, Prussian Blue (PB) staining can be used 
(Fig. 8c). A protocol for PB staining is given in Table 1. 
The cells can be labeled additionally using fluorescent dyes as GFP or PKH26, which may 
be helpful for histological examination after in vivo applications. This allows 
discrimination between initially labeled cells and cells that secondarily took up iron by 
endocytosis. 
 
step Prussian Blue staining duration 
1 Fixate in 4% paraformaldehyde  20 min 
2 
Stain with 2% potassium ferrocyanide, Trihydrate and  
1% hydrochloride acid in a 1:1 ratio. 
20 min 
3 Wash in PBS 5 min 
4 Stain in eosin  4 min 
5 Wash in PBS 5 min 
6 Conserve with glycerol (culture flasks) or mounting medium (slide)  
Table 1. Protocol for Prussian Blue staining of VSOP-labeled BMSC 
Impact of VSOP labeling on cell viability and T2 relaxation time 
The influence of 3.0 mM VSOP on cellular viability and magnetic labeling has been 
investigated for ovine BMSC in previous experiments. The viability was evaluated by the 
trypan blue dye exclusion test before labeling, immediately thereafter, as well as after 4 and 
24 hours. Viability was compared to that of unlabeled cells. The transverse relaxation time 
(T2) was measured at 0.47 T/ 20 MHz (Minispec, Bruker, Ettlingen, Germany) immediately 
and 24 hours after VSOP-labeling to examine labeling efficacy.  
Our own results show that cellular viability decreased to 86 ± 16 % immediately after 
labeling. At 4 hours after labeling, the cell viability rate remained unaltered (89 ± 14 %), 
but slightly declined to 75 ± 3 % after 24 hours (Fig. 9a). Relaxometry measurements 
resulted in T2 relaxation times of 1,888 ± 171 ms for unlabeled cells as compared to 434 ± 
147 ms for VSOP-labeled cells (p<0.01), indicating a reduction of T2-time to 23 ± 8% after 
VSOP labeling (Fig. 9b, white). This result was reproduced 24 hours after labeling (Fig. 9b, 
black). 
4.1.2 BMSC detection in vivo  
Since VSOP shorten T2 relaxation time, the particles can be detected by MRI using 
gradient echo sequences, in particular T2* weighted imaging. Alternatively, susceptibility 
weighted imaging (SWI) can be used. The main difference to T2* is the inclusion of phase 
information into the image acquisition (Haacke et al., 2009). This is of particular 
advantage in case that dephasing particles such as iron-oxide particles are present in the 
respective voxel. The dephasing results in a hypointense signal at a given echo time. 
However, this signal loss is not specific, as there are a multitude of other sources of signal 
voids, such as blood and air. 
The blooming effect is a well known phenomenon caused by iron oxide particles. Due to the 
augmented dephasing of proton spins, a major susceptibility artefact is depicted that 
exceeds the real dimension of the particle by a factor of up to 50. Hence, a small amount of 
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particles or labeled cells, or even single cells, can be detected by high field MRI (Dodd et al., 
1999; Shapiro et al., 2005) taking advantage of the blooming effect.  
 
Fig. 9. Viability and relaxometry of VSOP-labeled BMSC 
a) Viability during 24 hours after labeling, control treatment is set to 100%; b) Relaxometry 
of labeled and unlabeled BMSC. White bars: immediately; black bars: 24 hours after labeling 




sequence resolution TR TE duration 
T2* 0.83 x 0.66 x 0.50 mm 620 20 2 h 07 min 
SWI 0.56 x 0.39 x 0.25 mm 60 20 1h 29 min 
Table 2. Parameters of MR imaging for detection of VSOP-labeled cells in ovine brain; TR – 
repetition time, TE – echo time 
For in vivo detection of VSOP-labeled BMSC in the ovine brain a 3T MRI scanner 
(Magnetom Trio, Siemens AG, Munich, Germany) was used. After initial anesthesia the 
sheep was placed on the scanner table as described in 3.1.1 and shown in Fig. 10a. A flexible 
head coil (Siemens AG, Munich, Germany) was placed centrally above the brain (Fig. 10b). 
After a brief T2-weighted Turbo Spin Echo (TSE) sequence for anatomical orientation, SWI- 
and T2*-sequences were acquired with the field of view set to the region of transplantation. 
The sequence parameters are listed in Table 2. Two hours after transplantation, a distinct, 
ellipsoidal to circular hypointensity was detectable at all injection sites in T2* and SWI 
sequences (Fig. 11). This was not the case for control (saline) application without cells. 
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Histological examination allows discrimination of cellular signals to other sources of 
hypointense signal change (4.1.3). 
 
Fig. 10. MRI of sheep 
a) Position of sheep in MR scanner. The animal is fixed with adhesive tap;  
b) Image taken by the scanner’s monitoring camera. The head is placed on a position  
pad and covered with folio drape and a flexible head coil is used (white arrow).  
Potentially excreted saliva and rumen fluid are collected by a plastic bowl placed  
directly below the animal’s mouth 
The non-invasive detection of the transplanted cells allows longitudinal studies for up to six 
months in the individual animal for precise detection of migration and localization of 
transplanted cells (Jendelova et al., 2004; Stroh et al., 2004 and 2005). It can also be combined 
with stroke related MR-examinations and allows tracing of migration processes towards the 
lesion. 
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Fig. 11. MR and macroscopic view of 100,000 VSOP-labeled BMSC in the ovine brain 
a) susceptibility weighted imaging (SWI), b) phase image of SWI, c) T2* image, d) 
macroscopic view on brain slice. Black arrow indicates the macroscopically visible BMSC 
graft 
4.1.3 Neuropathology and ex vivo BMSC detection  
Animals are sacrificed during deep anesthesia by a single, intravenously injection of 20 mL 
pentobarbital (Eutha 77, Essex Pharma LtD, Munich, Germany). After death is confirmed 
(abscence of cardiac, respiratory and reflexive activity over a period of at least two minutes) 
the sheep is rapidly decapitated at the atlanto-occipital junction. The carotid arteries are 
exposed for perfusion. Blunt perfusion cannulas are placed in each artery and are fixed with 
stout thread. Initially, the head is perfused with 3 L PBS followed by 20 L 4% 
paraformaldehyde (PFA, Carl Roth GmbH & Co. KG, Karlsruhe, Germany). A roller pump 
system (Roth Cyclo II, Carl Roth GmbH & Co. KG, Karlsruhe, Germany) can be used for that 
purpose. After removal of skin, muscles and adnexes by a sharp knife, the cranial cavity is 
opened using an oscillating saw (KM-40, Heraeus GmbH, Hanau, Germany). After careful 
removal of the dura, the open cranium is fixated in 4% PFA for at least 24 hours. 
Afterwards, the brain is removed for immersion fixation for another 48 hours in PFA.  
Macroscopic examination of the brain comprises weighing, measuring of circumferences, 
and photographic documentation from all directions. Next, the brain is cut into 4 mm 
thick, coronal slices which are each photographed from rostral and occipital direction. 
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Usually, the transplantation procedure does not result in macroscopically visible brain 
tissue alterations. In a minor number of cases, a very small alteration is observable at the 
injection site (Fig. 12).  
 
 
Fig. 12. Ovine brain after stereotatic transplantation 
The insertion of the cannula may lead to a small alteration (black arrow) on the brain 
surface. 
The transplantation area is cut out of the associated brain slice, embedded in paraffin and 
cut into 4 µm thick sections for histological analysis. Hematoxylin/eosin staining 
according to Table 3 is recommended for histological overview and exclusion of bleeding. 
Prussian Blue staining (according to Table 1, step 2 - 6) is used for detection of VSOP-
labeled cells.  
 
step hematoxylin/eosin staining duration 
1 Stain in hematoxylin 2 min 
2 Wash in piped water 2 min 
3 Blue in warm piped water 10 min 
4 Stain in eosin  4 min 
5 Wash in pure water 5 min 
6 Conservation (dehydrating, mounting)   
Table 3. Protocol for hematoxylin/eosin staining 
Transplantation of 100,000 VSOP-labeled cells results in a brown spot at the transplantation 
site which was clearly visible in the coronal slice (Fig. 11d). Transplantation of PBS reveals 
no changes in the macroscopic view.  
Histological investigation by hematoxylin/eosin staining usually reveals a small cavity 
containing the labeled cells with scattered mononuclear cells within the transplantation site 
8 hours after transplantation. Occasionally, microbleedings may occur close to the injection 
site. In sheep transplanted with VSOP-labeled BMSC, PB-positive cells are clearly detected 
at the specified target region (Fig. 13). No migration of cells is observed 8 hours after 
transplantation. 
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Fig. 13. Histological analysis of 100,000 transplanted, VSOP-labeled BMSC after striatal 
application 
a) Overview of transplantation site stained with PB, scale bar: 500 µm; b) Magnification of 
PB staining, scale bar: 100 µm; c) hematoxylin/eosin staining of transplantation site, no 
microhemorrhages (e.g. due to cell injection) are detectable; bar: 100 µm 
4.2 Concept 2: Hemorrhage model 
4.2.1 Hemorrhage detection 
T1-, T2- and T2*-weighted MR sequences can be used for hemorrhage detection. The 
injection of autologous blood into the sheep brain usually results in a spheric to ellipsoid-
shaped blood clot, with the depot size depending on the injected blood volume. The MR 
signal characteristics of the hemorrhage differ depending on the temporal stage of the 
hemorrhage and the pulse sequence used (Kidwell & Wintermark, 2008). In the hyperacute 
stage, hemoglobin is still oxygenated and therefore diamagnetic, thus appearing iso- to 
hypointense in T1-weighted sequences (Fig. 14a) and hyperintense in T2-weighted MRI (Fig. 
15a). A hypointense rim is observable in T2* sequence (Fig. 14b and c). In contrast, 
methemoglobin is present in the sub-acute stage. Methemoglobin is paramagnetic and 
generates a hyperintensive signal in T1-weighted and a hypointensive signal in T2-weighted 
MRI. Later, the signal changes become hypointensive in T1- and T2-weigthed MRI due to 
the progressive biodegradation of hemoglobin into superparamagnetic hemosiderin  
 
 
Fig. 14. Imaging of stereotactically placed blood clot (1.8 mL, 3 hours old) in ovine brain for 
simulation of intracerebral hemorrhage using T1 weighted (a) and T2* weighted sequences 
(b). An acute occipital intracerebral bleed in a human patient (T2*, 2 hours after onset of 
visual disturbances, white arrow) is shown in c) for direct comparison. For more details, 
please refer to main text. Note an old left temporal ischemia (secondary diagnosis) in this 
particular patient (black arrow) 
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towards the chronic phase of a hemorrhage. Also, a blooming effect can be observed by the 
high iron oxide content of hemosiderin (4.1.2).  
Fig. 14 gives a direct comparison between a stereotactically injected blood depot in the 
sheep model and a hyperacute bleeding in a human patient (with symptom onset of approx. 
2 h before MRI) in T2* MRI. A hyperintense signal is clearly observable in the center of the 
injected blood in the sheep brain (b) and the hyperacute intracerebral hemorrhage in the 
human patient (c), whereas a clear hypointense rim can be detected in the outer areas of the 
hemorrhage in both subjects. This difference in the signal intensity is caused by oxygenated 
hemoglobin in the central areas and deoxygenated hemoglobin in the peripheral areas of the 
hemorrhage. This signal behavior is typical for a hyperacute hemorrhage within a timeframe 
of approximately 3 to 9 h after symptom onset in human beings (Howells et al., 2010). In 
summary, the blood-induced MR signal 3 hours after autologous blood injection in the 
sheep model shows the same characteristics to the situation found in the human patient. 
 
 
Fig. 15. MRI of induced, acute hemorrhage (1.5 mL) in the ovine brain 
a) T2-weighted TSE sequence with a clearly observable, hyperintensive area (blood clot), 
b) corresponding macroscopic view of brain slice 
Tissue preparation for gross pathology after hemorrhage modeling can be performed 
according to 4.1.3. The clearly observable cavity in Fig. 15b indicates the injection site. The 
tissue around the injection site was compressed during blood injection. Similar findings are 
reported from autopsies of human patients who died from massive intracerebral 
hemorrhage in early stages. 
5. Summary 
Stereotactic neurosurgery is a routine technique in human medicine. Stereotaxy-based local 
treatments of stroke (and other diseases) were effectively tested in rodents using strain- and 
weight-adapted coordinates and approaches. Hence, it is expected that intracerebral 
administration paradigms will be evaluated in upcoming clinical trials. However, a proof of 
concept of such treatment paradigms may be demanded in translational research, 
preferentially using large animal models. However, similar techniques were so far only 
available for primate models which are restricted to highly specialized centers.  
The described, frameless stereotaxy in sheep represents a novel and translational approach 
for neurosurgical applications in a widely available species. The used neuronavigation 
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system BrainSightTM was successfully adapted to the ovine skull anatomy. It allows an 
individual and accurate planning as well as precise execution of stereotactic interventions. 
Next to a detailed description of the technique itself, two relevant applications of the 
experimental techniques are reported in this chapter. First, the magnetic labeling and 
stereotactic transplantation of a stem cell population into the ovine brain is described. The 
methodology allows for precise injection and tracking of autologous stem cell populations 
using a widely available 3T MRI scanner. Relatively simple but reliable pathohistological 
techniques for post-mortem brain assessment and detection of transplanted cells are also 
given. Thus, the reported methodology may be used for evaluation of cell-based treatment 
strategies of central nervous system disorders in the gyrencephalic brain. Second, the 
stereotactic technique can be used for precise modeling of intracerebral hemorrhages by 
autologous blood injection in sheep. The observed results are in good correlation to those 
seen in human patients, especially regarding relevant diagnostic findings in MRI. 
Summarizing, stereotactic interventions in sheep represent a well applicable and reliable 
approach for translational research with a wide spectrum of possible applications. 
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